Advanced searches left 3/3

Influenza Vaccine - Springer Nature

Summarized by Plex Scholar
Last Updated: 11 September 2022

* If you want to update the article please login/register

Post-marketing Surveillance of a Quadrivalent Influenza Vaccine (Vaxigrip Tetra) in South Korea

Introduction In 2017, a quadrivalent inactivated split-virion influenza vaccine was approved in South Korea for effective immunization against influenza A and influenza B viruses in people aged 3 years or older, which was later extended to those aged 6 months or older in 2018. Here, we investigated the effectiveness of QIV in routine clinical practice in South Korea. Methods This was an open, multicenter, observational, active safety surveillance study that was conducted at ten study centers in South Korea between 20 June 2017 and 19 June 2021 in individuals aged 3 years or older who received a single dose of QIV during a routine healthcare visit. The most common solicited injection site reaction was pain in injection site pain, with myalgia and malaise being the most common solicited systemic reactions.

Source link: https://doi.org/10.1007/s40121-022-00685-x


Advanced biological age is associated with improved antibody responses in older high-dose influenza vaccine recipients over four consecutive seasons

Before and post-vacation in adults over 65 years old using a panel of ten serological biomarkers as part of the BioAge R package, we calculated biological age using data and biosamples from a 4-year clinical trial comparing immune responses of standard- and high-dose influenza vaccination. Prior to vaccination and 4-, 10-, and 20-week post-vaccination, Hemagglutination inhibition antibody titres against influenza A/H1N1, A/H3N1, A/H3N2 and B were determined against influenza A/H1N1, A/H3N2, B/H3N2 and B. However, this was highly dependent on both vaccine dose and CMV serostatus, as these were only apparent among high-dose recipients — and far less for CMV positive high-dose recipients. These findings highlight two key areas: first, the loss of physiological integrity due to biological age may not be a common cause of immune decline in older adults, and second, latent causes such as CMV infection can contribute to the heterogeneity in vaccine responses of older adults more than previously believed.

Source link: https://doi.org/10.1186/s12979-022-00296-7


The effect of influenza vaccine in reducing the severity of clinical outcomes in patients with COVID-19: a systematic review and meta-analysis

According to recent studies, vaccination against influenza may have a reduction in COVID-19's clinical outcomes. This report investigated the connection between influenza vaccination and the severity of COVID-19 infections. We included research that reported the connection between influenza vaccination and COVID-19 outcomes. The results were pooled as a risk ratio or mean difference, with 95% confidence intervals, and the results were pooled using fixed and random effects models, according to the heterogeneity of results. Sixteen observational studies with 191,496 COVID-19 patients were included. There were no significant differences between those who had received the influenza vaccine and those that did not have COVID-19 clinical outcomes, except for mechanical ventilation, which presented a substantial reduced risk in the influenza vaccinated group relative to the non-vaccinated group. This does not ignore the importance of the influenza vaccine during the COVID-19 pandemic.

Source link: https://doi.org/10.1038/s41598-022-18618-6

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions